Biomarker-focused multi-drug combination therapy and repurposing trial in mdx mice
暂无分享,去创建一个
E. Hoffman | Y. Hathout | K. Uaesoontrachoon | K. Nagaraju | H. Gordish-Dressman | M. Giri | Utkarsh J Dang | Michael Ziemba | Molly Barkhouse
[1] R. Finkel,et al. Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function , 2019, Neuromuscular Disorders.
[2] Heeyoung Lee,et al. Comparative Efficacy and Safety of Biosimilar Rituximab and Originator Rituximab in Rheumatoid Arthritis and Non-Hodgkin’s Lymphoma: A Systematic Review and Meta-analysis , 2019, BioDrugs.
[3] E. Hoffman. Pharmacotherapy of Duchenne Muscular Dystrophy. , 2019, Handbook of experimental pharmacology.
[4] R. Inagi,et al. SMPDL3b modulates insulin receptor signaling in diabetic kidney disease , 2019, Nature Communications.
[5] T. Kuzel,et al. The Discovery of Biomarkers in Cancer Immunotherapy , 2019, Computational and structural biotechnology journal.
[6] E. Hoffman,et al. Vamorolone targets dual nuclear receptors to treat inflammation and dystrophic cardiomyopathy , 2019, Life Science Alliance.
[7] Y. Horio,et al. Resveratrol Ameliorates Mitophagy Disturbance and Improves Cardiac Pathophysiology of Dystrophin-deficient mdx Mice , 2018, Scientific Reports.
[8] E. Hoffman,et al. Serum biomarkers of glucocorticoid response and safety in anti-neutrophil cytoplasmic antibody-associated vasculitis and juvenile dermatomyositis , 2018, Steroids.
[9] R. Finkel,et al. Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first‐in‐class dissociative steroidal anti‐inflammatory drug , 2018, Pharmacological research.
[10] E. Hoffman,et al. Membrane Stabilization by Modified Steroid Offers a Potential Therapy for Muscular Dystrophy Due to Dysferlin Deficit , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.
[11] E. Hoffman,et al. Muscle miRNAome shows suppression of chronic inflammatory miRNAs with both prednisone and vamorolone , 2018, Physiological genomics.
[12] Ian Mitchelle S. de Vera,et al. Cryptic glucocorticoid receptor-binding sites pervade genomic NF-κB response elements , 2018, Nature Communications.
[13] Taeseung Lee,et al. β-aminoisobutyric acid attenuates LPS-induced inflammation and insulin resistance in adipocytes through AMPK-mediated pathway , 2018, Journal of Biomedical Science.
[14] E. Hoffman,et al. Phase 1 trial of vamorolone, a first-in-class steroid, shows improvements in side effects via biomarkers bridged to clinical outcomes , 2018, Steroids.
[15] M. Goddeeris,et al. PPARδ modulation rescues mitochondrial fatty acid oxidation defects in the mdx model of muscular dystrophy. , 2018, Mitochondrion.
[16] Ying Sun,et al. Proteomic analysis reveals distinctive protein profiles involved in CD8+ T cell-mediated murine autoimmune cholangitis , 2018, Cellular & Molecular Immunology.
[17] J. Assreuy,et al. New Insights in Glucocorticoid Receptor Signaling—More Than Just a Ligand-Binding Receptor , 2017, Front. Endocrinol..
[18] E. Hoffman,et al. Identification of Pathway-Specific Serum Biomarkers of Response to Glucocorticoid and Infliximab Treatment in Children with Inflammatory Bowel Disease , 2016, Clinical and Translational Gastroenterology.
[19] Kristy Brown,et al. Serum pharmacodynamic biomarkers for chronic corticosteroid treatment of children , 2016, Scientific Reports.
[20] E. Hoffman,et al. Prednisone/prednisolone and deflazacort regimens in the CINRG Duchenne Natural History Study , 2015, Neurology.
[21] E. Hoffman,et al. Immune-mediated pathology in Duchenne muscular dystrophy , 2015, Science Translational Medicine.
[22] Eric P. Hoffman,et al. Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy , 2015, Proceedings of the National Academy of Sciences.
[23] Kristy Brown,et al. Discovery of serum protein biomarkers in the mdx mouse model and cross-species comparison to Duchenne muscular dystrophy patients. , 2014, Human molecular genetics.
[24] E. Hoffman,et al. Asynchronous remodeling is a driver of failed regeneration in Duchenne muscular dystrophy , 2014, The Journal of cell biology.
[25] Chad A. Cowan,et al. β-Aminoisobutyric acid induces browning of white fat and hepatic β-oxidation and is inversely correlated with cardiometabolic risk factors. , 2014, Cell metabolism.
[26] Kristy Brown,et al. Sparing of the dystrophin-deficient cranial sartorius muscle is associated with classical and novel hypertrophy pathways in GRMD dogs. , 2013, The American journal of pathology.
[27] E. Hoffman,et al. VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects , 2013, EMBO molecular medicine.
[28] E. Hoffman,et al. The paradox of muscle hypertrophy in muscular dystrophy. , 2012, Physical medicine and rehabilitation clinics of North America.
[29] Tracy R. Keeney,et al. From SOMAmer-Based Biomarker Discovery to Diagnostic and Clinical Applications: A SOMAmer-Based, Streamlined Multiplex Proteomic Assay , 2011, PloS one.
[30] M. Rastaldi,et al. Rituximab Targets Podocytes in Recurrent Focal Segmental Glomerulosclerosis , 2011, Science Translational Medicine.
[31] F. Bieber,et al. Dystrophin analysis in duchenne muscular dystrophy: use in fetal diagnosis and in genetic counseling. , 1989, American journal of human genetics.